Search

Doege–Potter syndrome (DPS) is a paraneoplastic syndrome characterized by nonislet cell tumor hypoglycemia due to a solitary fibrous tumor, which produces insulin-like growth factor II. In this report, we present the case of a 67-year-old male with recurrent and refractory hypoglycemia due to DPS successfully treated with imatinib. He initially presented with neuroglycopenic symptoms and dyspnea secondary to a giant tumor in the left hemithorax, which was totally resected. During follow-up, 7 years later, he presented with thoracoabdominal tumor recurrence associated with severe hypoglycemia and underwent subtotal tumor resection, with a subsequent improvement of symptoms. The following year, he had a recurrence of his intra-abdominal tumor, which was unresectable, associated with severe hypoglycemia refractory to dextrose infusion and corticosteroids, thus receiving imatinib with a favorable response. The clinical presentation, diagnostic approach, progression of the disease, and response to treatment with imatinib in the management of a patient with large, recurrent, and unresectable mesenchymal tumors with insulin-like growth factor-2 secretion causing hypoglycemia highlight the importance of this case report.

Objetivo: Evaluar la relación entre control metabólico y enfermedad arterial periférica (EAP) en pacientes con diabetes mellitus tipo 2 (DM2) del hospital María Auxiliadora (HMA). Material y métodos: Estudio caso-control pareado para sexo, de un análisis secundario basado en datos del servicio de endocrinología del HMA, Lima-Perú. Los casos con EAP, fueron aquellos con índice tobillo-brazo (ITB) < 0,9. Los controles fueron aquellos con ITB entre 0,9 y 1,3 en una relación 4:1 con respecto a los casos. Se definió como mal control metabólico si presentaron al menos uno de las siguientes: hemoglobina glicosilada ≥ 7 %, presión arterial sistólica ≥ 140 mm Hg, presión arterial diastólica ≥ 90 mm Hg, colesterol HDL< 40 mg/dl (varón) o < 50 mg/dl (mujer), colesterol LDL ≥ 100 mg/dl y triglicéridos ≥ 150 mg/dl. Se calculó el Odds ratio (OR) de mal control metabólico, tanto crudo como ajustado, según presencia de EAP mediante regresión logística. Resultados: Incluimos a 39 casos y 157 controles. Un 94,9 % y 82,2 % de los casos y controles presentaron mal control metabólico respectivamente (p